- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT01731015
Imaging Lung Function Using Oxygen Enhanced MRI
A Pilot Study for Evaluation of Regional Lung Function in Normal Subjects and Subjects With Airway and Lung Disorders Using 1H Magnetic Resonance Imaging With Oxygen as a Contrast Agent
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
This is an open label study expanding on work by other groups in animals, ex-vivo human lungs and human subjects. Both 2-dimensional and 3-dimensional images will be obtained using 1H MRI comparing images obtained while breathing oxygen to those obtained breathing room air.
Objectives
- To determine if 1H magnetic resonance images of the human lung and airways can be obtained in both single breath-hold and gated breathing imaging studies with adequate signal level and image contrast to extract regional lung functional information with oxygen as a contrast agent.
- To determine the short term reproducibility of the lung functional imaging in a subset of subjects (5 control subjects and 5 subjects with lung disease) with repeat MRI studies (Visit 2) at a time point ≥ 1 week to ≤ 4 weeks from Visit 1
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 1. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
North Carolina
-
Durham, North Carolina, Egyesült Államok, 27705
- Duke University Medical Center
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria for Lung and/or Airway Disease
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
- Subjects must be ≥ 18 years of age;
Evidence of lung disease or injury by medical history, physical exam, and/or clinical laboratories;
- COPD
- Asthma
- Pre/Post Lung Transplant
- Cystic Fibrosis
- Emphysema/Other Small Airways Diseases
- Lung Transplant
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
- Subjects who are willing and able to comply with scheduled visits and other trial procedures.
Exclusion Criteria for Subjects with Lung and/or Airway Disease:
Subjects presenting with any of the following will not be included in the trial:
- Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of contraindications (e.g. metal in the eye, claustrophobia);
- Unable to receive 100% oxygen by breathing because of potential hypercapnia ( SpO2 <90% or FEV1 < 1 L);
- Participation in a clinical trial with a study drug that may impact lung function in the past 14 days; or
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial. This determination is made by the referring physician based on standard clinical practice.
- Female; women of childbearing potential must have a confirmed negative urine pregnancy test on the day of the MR scan, prior to the MRI scan.
Inclusion Criteria for Normal Subjects Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
- Subjects must be ≥ 18 years of age;
- Non-smokers, ex-smokers with normal pulmonary function test by spirometry;
- No Evidence of prior lung disease or lung injury by medical history, physical exam, and/or clinical laboratories;
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
- Subjects who are willing and able to comply with scheduled visits and other trial procedures.
Exclusion Criteria for Normal Subjects
Subjects presenting with any of the following will not be included in the trial:
- Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of contraindications (e.g. metal in the eye, claustrophobia);
- Unable to receive 100% oxygen by breathing because of potential hypercapnia (SpO2 <90% or FEV1 < 1 L) (Note, we consider this highly unlikely in a 'normal' subject);
- Participation in a clinical trial with a study drug that may impact lung function in the past 14 days; or
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
- Female; women of childbearing potential must have a confirmed negative urine pregnancy test on the day of the MR scan, prior to the MRI scan.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Diagnosztikai
- Kiosztás: Nem véletlenszerű
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: Normal Subject
Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures.
The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system.
No additional drug products, investigational or otherwise will be provided in this study.
|
At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)).
Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent.
For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging.
Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience ~ 1-2 minutes).
The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air.
After steady state is achieved a second room air scan is completed.
Más nevek:
|
Kísérleti: Subjects with Lung/or Airway Disease
Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures.
The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system.
No additional drug products, investigational or otherwise will be provided in this study.
|
At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)).
Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent.
For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging.
Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience ~ 1-2 minutes).
The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air.
After steady state is achieved a second room air scan is completed.
Más nevek:
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Image Quality
Időkeret: one exposure
|
Assessment of image quality of oxygen enhanced MR images: Signal to Noise Ratio, Dynamic Range of Ratio/Difference Images
|
one exposure
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Kutatásvezető: Cecil Charles, PhD, Duke University
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Becslés)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- Pro00024828
- DIAL1001002 (Egyéb azonosító: Duke University Medical Center)
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Medical Grade Oxygen
-
ReiThera SrlIstituto Nazionale per le Malattie Infettive Lazzaro SpallanzaniBefejezve
-
ReiThera SrlIstituto Nazionale per le Malattie Infettive Lazzaro SpallanzaniBefejezve
-
Soterix MedicalGeorgetown University; National Institute of Neurological Disorders and Stroke (NINDS) és más munkatársakBefejezveKrónikus afáziaEgyesült Államok
-
Soterix MedicalNYU Langone HealthBefejezveKezelésrezisztens depresszió | Unipoláris depresszióEgyesült Államok
-
Abbott Medical DevicesBefejezveTachycardiaNémetország, Észtország
-
University of WashingtonBefejezveÉgési sérülés utáni hipertrófiás hegesedésEgyesült Államok
-
Baylor College of MedicineAktív, nem toborzóNeurális cső hibáiEgyesült Államok
-
Abbott Medical DevicesMegszűnt
-
Cordio MedicalBefejezveSzív elégtelenségIzrael